Crinetics Pharmaceuticals' stock surged 99% following an announcement that Vertex Pharmaceuticals agreed to acquire the biotech company for $10 billion. This significant deal highlights Vertex's expansion strategy in the biotech sector. Investors reacted strongly to the news, driving Crinetics' stock price sharply higher. The acquisition is expected to close after regulatory approvals, potentially reshaping the biotech landscape.
Brodsky & Smith law firm is investigating the Board of Directors of Crinetics Pharmaceuticals for potential breaches of fiduciary duty related to the company's sale to Vertex Pharmaceuticals for $85 per share, totaling about $10 billion. The probe qu...
NATO leaders are meeting in Ankara to address rising tensions within the alliance, especially between the U.S. and European members over defense spending and military commitments. The summit aims to secure a joint declaration for increased European d...
Global semiconductor stocks fell sharply overnight across major markets, dragging Nasdaq 100 futures lower ahead of the U.S. open. Despite strong earnings like Samsung's record profit, chip stocks including SK Hynix, Tokyo Electron, and Taiwan Semico...
